Under the Sun Client: Kasta Travel Year: 2023 This is placeholder text. To change this content, double-click on the element and click Change Content. To manage all your collections, click on the Content Manager button in the Add panel on the left. Previous Next

Learn more about Dr. George M. Ekema, the visionary founder of Ablatotech. An award-winning drug discovery scientist and accomplished patent lawyer, Dr. Ekema is dedicated to advancing biotherapeutics and Dr. George Ekema: Visionary Leader of Ablatotech’s Healthcare Revolution Driven by an unrelenting passion for transforming lives, Dr. George Ekema., cofounder and CEO of Ablatotech, stands as a pioneering force in the world of biotechnology. From a young age, Dr. Ekema exhibited an unquenchable thirst for knowledge, which led him to move to the United States in his teens to pursue a remarkable journey in biomedical sciences. With BS degrees in biology and chemistry, a PhD in biomedical sciences specializing in neuroscience, and a JD in intellectual property law, Dr. Ekema brings a rare blend of scientific mastery and legal expertise to his role as CEO—a combination that uniquely positions him to revolutionize the healthcare industry. With over two decades of experience as a drug discovery and therapeutics scientist, Dr. Ekema's career has been defined by an audacious goal: to cure the incurable. He began by discovering and validating therapeutic targets before advancing into small molecule drug discovery and development. Yet, he quickly recognized that true innovation lies not in inventing external "weapons" to combat disease but in empowering the body’s natural capacity to heal itself. This transformative revelation became the foundation of Ablatotech’s mission. My Story Guided by the principle that the human body, when properly supported, is its own best defender, Dr. Ekema has redefined what is possible in medicine. His leadership at Ablatotech has focused on creating groundbreaking therapeutics—tools that act as "boxing gloves" for the body’s prized fighter, enabling it to deliver knockout blows to cancer, infectious diseases, chronic illnesses, and even aging itself. Ablatotech’s flagship technology, Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP) , reflects Dr. Ekema’s visionary approach , delivering safer, highly effective, and incredibly affordable solutions that are accessible to even the most underserved populations. With an inspiring blend of scientific brilliance, entrepreneurial spirit, and humanitarian dedication, Dr. Ekema is not just leading Ablatotech—he is spearheading a global revolution in healthcare. His ability to merge cutting-edge innovation with a deep commitment to equity and impact leaves no doubt that he is the right person to drive the future of medicine forward. At Ablatotech, under Dr. Ekema’s transformative leadership, the vision of delivering the future of medicine today is not just a promise—it’s a rapidly unfolding reality.

Landscape Magazine Photoshoot Client: Landscape Magazine Year: 2023 This is placeholder text. To change this content, double-click on the element and click Change Content. To manage all your collections, click on the Content Manager button in the Add panel on the left. Previous Next

At Ablatotech, we are rewriting the rules of medicine by harnessing the body’s natural potential to heal. Born out of the visionary mind of Dr. George Ekema—an award-winning drug discovery scientist and accomplished patent lawyer—Ablatotech stands at the forefront of biotherapeutic innovation. With a profound commitment to transforming lives, we are dedicated to developing groundbreaking technologies that not only trick the body into healing itself but also amplify its innate ability to do so. Pioneering the Future of Healing At Ablatotech, we are rewriting the rules of medicine by harnessing the body’s natural potential to heal and thrive. Born out of the visionary mind of Dr. George Ekema —an award-winning drug discovery scientist and accomplished patent lawyer—Ablatotech stands at the forefront of biotherapeutic innovation. With a profound commitment to transforming lives, we are dedicated to developing groundbreaking technologies that not only trick the body into healing itself but also amplify its innate ability to recover and regenerate. Our flagship innovation, Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), is set to redefine the healthcare industry. DAPYTAP enables us to create drugs that are not only safer and more effective than current treatments but also incredibly affordable—reaching even the world’s most underserved populations. Imagine a future where revolutionary therapies are within reach for everyone, from the wealthiest nations to the poorest villages. This is the vision driving Ablatotech forward. Our mission is bold yet clear: to disrupt the healthcare landscape by delivering biotherapeutics that break barriers in accessibility, efficacy, and safety. Through relentless innovation, Ablatotech is poised to lead a paradigm shift, transforming medicine from a system of treatment into one of natural healing and self-repair. For investors seeking to be part of a monumental change in global healthcare, Ablatotech is your opportunity to not only generate impact but to be part of a legacy. Together, we are shaping a world where healing knows no borders, and hope is universal. Welcome to the future of medicine—welcome to Ablatotech.

At Ablatotech, our platform technologies use natural means to stimulate the body to heal itself. Our therapies stimulate natural healing. It is a safer and more efficient way to prevent and cure diseases. For example, with our BACTRAIN technology, we 'train' friendly bacteria, and other beneficial microbes Our Core Technology Direct Antigen Presentation via Yeast for Treating and Preventing Disease (DAPYTAP) At Ablatotech, we are at the forefront of a healthcare revolution, unlocking the body’s inherent capacity to heal itself and amplifying its natural resilience. Our groundbreaking platform, Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), is redefining what is possible in modern medicine. With DAPYTAP, we are creating a new era of biotherapeutics—safe, highly effective drugs that are remarkably affordable. This innovation enables us to bring life-saving treatments to those in even the most underserved regions, ensuring that cutting-edge healthcare becomes a reality for all, not just a privilege for a few. Ablatotech's vision goes beyond incremental improvements; we aim to disrupt and transform the healthcare industry by making healing accessible, equitable, and revolutionary. By bridging advanced science with practical solutions, we are delivering therapies that set new standards in efficacy and safety, while breaking cost barriers that have long limited global reach. Join us in reshaping the future of medicine—this is innovation with impact, innovation for humanity. Ablatotech is where science meets a profound commitment to improving lives on a global scale. DAPYTAP is a better alternative to monoclonal antibody therapy If it can be treated with monoclonal antibodies, it can be treated better with DAPYTAP. Some of the conditions that DAPYTAP might do much better than monoclonal antibodies include: (1) Kidney transplant rejection (2) Prevention of blood clots in angioplasty (3) Non-Hodgkin lymphoma (4) Prevention of respiratory syncytial virus infection (5) Crohn’s disease (6) Breast cancer (7) Chronic myeloid leukemia (8) Rheumatoid arthritis (9) Asthma (10) Colorectal cancer (11) Multiple sclerosis (12) Macular degeneration (13) Paroxysmal nocturnal hemoglobinuria (14) Psoriasis (15) Muckle-Wells syndrome (16) Rheumatoid and psoriatic arthritis (17) Ankylosing spondylitis (18) Chronic lymphocytic leukemia (19) Bone loss (20) Systemic lupus erythematosus (21) Metastatic melanoma (22) Hodgkin lymphoma (23) Systemic anaplastic large cell lymphoma (24) Castleman disease (25) Gastric cancer (26) Ulcerative colitis (27) Acute lymphoblastic leukemia (28) Non-small cell lung cancer (29) Neuroblastoma (30) Severe eosinophilic asthma (31) High cholesterol (32) Multiple myeloma (33) Soft tissue sarcoma (34) Prevention of Clostridium difficile infection recurrence (35) Bladder cancer (36) Prevention of inhalational anthrax (37) Atopic dermatitis (38) Merkel cell carcinoma (39) Multiple sclerosis (40) Hemophilia A (41) X-linked hypophosphatemia (42) Hereditary angioedema attacks (43) Mycosis fungoides (44) Sézary syndrome (45) Migraine prevention (46) Cutaneous squamous cell carcinoma (47) Primary hemophagocytic lymphohistiocytosis (48) HIV infection (49) Hairy cell leukemia (50) Acquired thrombotic thrombocytopenic purpura (51) Osteoporosis (52) Diffuse large B-cell lymphoma (53) Sickle cell disease

Introducing Ablatotech's Nygela clinical trials: a natural cream targeting skin disorders like acne, eczema, and psoriasis. Discover innovative solutions for healthier skin through advanced research. Join the Clinical Trial for Nygela Topical Cream Are you living with psoriasis, eczema, or acne? Ablatotech, a leader in innovative biotherapeutics, is excited to announce a groundbreaking clinical trial for a natural, topical cream designed to redefine how we care for chronic skin conditions. This revolutionary solution aims to be a cost-effective, safer, and more effective alternative to immune-suppressing drugs currently on the market. Our mission is simple: to harness the power of nature and cutting-edge science to deliver relief and improve the lives of those affected by these conditions. As a participant in this study, you will play a vital role in shaping the future of skincare treatments while receiving expert guidance and support throughout the trial. Key Details: This study is open to adults aged 18–65 with mild-to-moderate psoriasis, eczema, or acne. Participants will apply the topical cream as directed over a 12-week period. The trial includes regular check-ins with our team to ensure safety and monitor progress. Why Join? Be part of an innovative effort to transform skincare therapies. Gain access to cutting-edge, natural treatments at no cost. Help advance science and improve options for millions worldwide. 📅 Enrollment is now open, but spaces are limited! Be a part of this healthcare revolution today. Use the form below to sign up now! First Name Last Name Email Location Phone Year of Birth Race Select a Race Ethnicity Enter your ethnicity Gender Select a gender Condition Choose an option I agree to the terms & conditions View terms of use Sign Up Submitted! Thanks for your interest in Nygela clinical trials.

At Ablatotech, we envision a world where healing is no longer a privilege, but a universal right. We are pioneering transformative biotherapeutics that naturally empower the body to heal itself and amplify its innate resilience. Through revolutionary innovations like Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), we are breaking barriers in biotechnology to create safer, more effective, and profoundly affordable treatments that redefine healthcare. Our Vision At Ablatotech, we envision a world where healing is no longer a privilege, but a universal right. Harnessing the extraordinary potential of the human body, we are pioneering transformative biotherapeutics that naturally empower the body to heal itself and amplify its innate resilience. Through revolutionary innovations like Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), we are breaking barriers in biotechnology to create safer, more effective, and profoundly affordable treatments that redefine global healthcare. Imagine a future where life-saving therapies are accessible to every corner of the globe, from bustling cities to the most underserved communities. DAPYTAP not only offers the promise of unparalleled efficacy but also delivers a paradigm shift—drastically reducing costs to make cutting-edge medicine attainable for all. With Ablatotech, we are not just improving lives; we are dismantling outdated systems, disrupting the healthcare industry as we know it, and leading the charge toward a healthier, more equitable world. Invest in Ablatotech, and join us in shaping a future where innovation knows no bounds, and humanity thrives. Together, let’s revolutionize the very foundation of healthcare. Preventing and treating diseases with DAPYTAP No drug can heal the body better than the body can heal itself. Like a prizefighter all the body needs is the right signals and stimulation, like those from DAPYTAP, to completely heal and protect itself. Reversing aging with DAPYTAP We are redefining what is means to grow old. Having a second chance to grow old is within grasp. What would you do with your second chance?

Potential Treatments on the Horizon (other than DAPYTAP) Potential Treatments on the Horizon (Other than DAPYTAP) This is your About page. This space is a great opportunity to give a full background on who you are, what you do and what your site has to offer. Your users are genuinely interested in learning more about you, so don’t be afraid to share personal anecdotes to create a more friendly quality. Every website has a story, and your visitors want to hear yours. This space is a great opportunity to provide any personal details you want to share with your followers. Include interesting anecdotes and facts to keep readers engaged. Double click on the text box to start editing your content and make sure to add all the relevant details you want site visitors to know. If you’re a business, talk about how you started and share your professional journey. Explain your core values, your commitment to customers and how you stand out from the crowd. Add a photo, gallery or video for even more engagement. Let’s Work Together Get in touch so we can start working together.

Join the Groundbreaking Clinical Trials for Tarysol – A Revolutionary Treatment for Thrombosis Are you or a loved one living with blood clot-related health conditions? Ablatotech is conducting clinical trials for Tarysol, a natural, cutting-edge drug designed to rapidly and safely dissolve blood clots within hours. We are seeking volunteers to participate in this pivotal research that has the potential to transform the treatment of thrombosis and improve countless lives. Your participation could help advance medical science and offer new hope for those affected by blood clots. Eligibility Requirements: We are looking for individuals who: Have been diagnosed with thrombosis or related blood clot conditions. Meet specific health criteria as determined during the screening process. Are willing to attend scheduled appointments and adhere to study protocols. Why Participate? Contribute to groundbreaking medical innovation. Access a promising investigational treatment under expert medical supervision. Receive medical care and potential compensation for your time and travel. Your journey as a participant in this study will help shape the future of thrombosis treatment, bringing us closer to safer, more effective solutions for blood clot-related conditions. Contact Us to Learn More If you are interested in participating or would like to know more about the Tarysol clinical trials, please contact: Email: info@ablatotech.com Act now to take part in this life-changing research. Together, we can redefine the future of thrombosis treatment! First Name Last Name Email Location Phone Year of Birth Race Select a Race Ethnicity Enter your ethnicity Gender Select a gender Condition Choose an option I agree to the terms & conditions View terms of use Sign Up Submitted! Thanks for your interest in Tarysol clinical trials.

Terms and Conditions for Participation in Liprovia Clinical Trials Effective Date: 02/12/2025 Last Updated: 3/14/2025 1. Acceptance of Terms By applying to participate in the Liprovia clinical trials conducted by Ablatotech, you acknowledge that you have read, understood, and agreed to abide by these Terms of Use. Submission of an application does not guarantee inclusion in the trial; final selection is determined after a detailed screening process. 2. Purpose of Clinical Trial The Liprovia clinical trial aims to evaluate the safety, effectiveness, and tolerability of Liprovia, an oral, natural GLP-1 agonist-like drug developed for weight loss. By participating, you are contributing to research that may advance medical solutions for weight management. 3. Voluntary Participation Participation in this trial is entirely voluntary. You may choose to withdraw your application or discontinue your participation at any time without penalties or consequences. 4. Eligibility Requirements To apply for the Liprovia clinical trials, you must meet the eligibility requirements established for the study, which include but are not limited to: Meeting specific age and health criteria outlined during the screening process. Absence of certain pre-existing medical conditions, which will be disclosed during initial assessments. 5. Screening and Selection Applicants will be required to complete a thorough screening process, including: Submission of medical history and relevant documentation. Completion of health-related questionnaires. Attendance at diagnostic evaluations, if required. Ablatotech reserves the right to decline applications from individuals who do not meet eligibility criteria or pose safety risks. 6. Privacy and Data Protection Your personal and medical data will be treated with strict confidentiality. Ablatotech adheres to data protection laws such as HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation). Your information will be used solely for research purposes in a de-identified format. 7. Risks and Benefits Participants should be aware of the following: Risks: Use of Liprovia may involve potential side effects or adverse reactions. These will be detailed during the informed consent process. Benefits: While personal health benefits cannot be guaranteed, your participation contributes to research that may benefit others in the future. 8. Informed Consent Participants must review and sign an Informed Consent Form before being enrolled in the study. This document will outline in detail the purpose, procedures, potential risks, and benefits of the clinical trial. 9. Participant Responsibilities By enrolling in the Liprovia clinical trials, participants agree to: Comply with all study protocols, including medication guidelines and follow-up assessments. Attend all scheduled appointments and notify the research team of any side effects or adverse events. Provide accurate and truthful information throughout the trial period. 10. Compensation Participants may be eligible for compensation to cover time, travel, and related expenses. Details will be discussed and agreed upon before enrollment. 11. Medical Care and Support In case of harm or adverse effects directly resulting from participation in the clinical trial, Ablatotech will provide appropriate medical care as outlined in the Informed Consent Form. 12. Termination of Participation Ablatotech reserves the right to terminate a participant’s involvement in the trial if: Safety concerns arise. Study protocols are not followed. Continued participation becomes inappropriate for health reasons. 13. Intellectual Property All data, discoveries, and intellectual property resulting from the Liprovia clinical trial are the sole property of Ablatotech. Participants will not receive ownership rights or additional compensation beyond what is specified in the agreement. 14. Limitation of Liability Ablatotech is not responsible for any damages beyond those explicitly stated in the informed consent documentation, except as required by law. 15. Amendments to Terms These Terms of Use are subject to change. Participants will be notified of significant updates, and continued participation constitutes agreement to the revised terms. 16. International Participation Clinical trials for Liprovia are currently open only to individuals residing outside of the United States. Applicants from international locations will be evaluated under the same rigorous standards as domestic participants. 17. Pre-screening medical questionaire Providing answers to the pre-screening medical questionaire is voluntary. If providing that information, you could remain anonymous by not providing your last name. 18. Contact Information For inquiries or concerns regarding the Liprovia clinical trials, please contact: Email: info@ablatotech.com Acknowledgment and Agreement By submitting an application for the Liprovia clinical trials, you affirm that you have read, understood, and agreed to these Terms of Use.